Standard BioTools Inc.
DB:FLB Stock Report
Standard BioTools Past Earnings Performance Standard BioTools's earnings have been declining at an average annual rate of -21.4%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been declining at an average rate of 0.4% per year.
Key information
-21.4%
Earnings growth rate
Life Sciences Industry Growth 26.8% Revenue growth rate -0.4% Return on equity -25.5% Net Margin -109.4% Last Earnings Update 30 Sep 2024
Recent past performance updates
Third quarter 2024 earnings released: US$0.073 loss per share (vs US$0.27 loss in 3Q 2023) Nov 01
Standard BioTools Inc. to Report Q3, 2024 Results on Oct 30, 2024 Oct 16
Second quarter 2024 earnings released: US$0.12 loss per share (vs US$0.22 loss in 2Q 2023) Aug 01
Standard BioTools Inc. to Report Q2, 2024 Results on Jul 31, 2024 Jul 17
Standard BioTools Inc. to Report Q1, 2024 Results on May 08, 2024 Apr 27
Full year 2023 earnings released: US$0.94 loss per share (vs US$2.43 loss in FY 2022) Feb 29
Show all updates Standard BioTools Inc. Announces the Appointment of Alex Kim as Chief Financial Officer, Effective November 11, 2024
Standard BioTools Inc. Reiterates Revenue Guidance for Full Year 2024 Nov 02
Third quarter 2024 earnings released: US$0.073 loss per share (vs US$0.27 loss in 3Q 2023) Nov 01
Standard BioTools Inc. to Report Q3, 2024 Results on Oct 30, 2024 Oct 16
No longer forecast to breakeven Aug 02
Standard BioTools Inc. Revises Revenue Guidance for the Full Year 2024 Aug 02
New major risk - Share price stability Aug 01
Second quarter 2024 earnings released: US$0.12 loss per share (vs US$0.22 loss in 2Q 2023) Aug 01
Standard BioTools Inc. Announces Chief Financial Officer Changes Aug 01
High number of new and inexperienced directors Jul 25
Standard BioTools Inc. to Report Q2, 2024 Results on Jul 31, 2024 Jul 17
Standard BioTools Inc., Annual General Meeting, Jun 27, 2024 May 24
Standard BioTools Inc. Reaffirms Revenue Guidance for the Fiscal Year 2024 May 10
Standard BioTools Inc. to Report Q1, 2024 Results on May 08, 2024 Apr 27 Standard BioTools Inc. Announces Operational Restructuring Plan Apr 26
Now 23% overvalued after recent price rise Apr 12
Standard BioTools Inc. Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the Boundaries of Tissue Imaging Apr 09
Forecast to breakeven in 2026 Mar 03
New major risk - Financial position Mar 01
Standard BioTools Inc. Provides Revenue Guidance for the Full Year 2024 Mar 01
Full year 2023 earnings released: US$0.94 loss per share (vs US$2.43 loss in FY 2022) Feb 29
Standard BioTools Inc. to Report Q4, 2023 Results on Feb 28, 2024 Feb 15
New major risk - Revenue and earnings growth Jan 09
Standard Biotools Inc. Provides Revenue Guidance for the Fourth Quarter and full year 2023 Jan 09 SomaLogic, Inc. (NasdaqGM:SLGC) completed the acquisition of Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others.
Third quarter 2023 earnings released: US$265 loss per share (vs US$0.37 loss in 3Q 2022) Nov 09
Standard BioTools Inc. to Report Q3, 2023 Results on Nov 07, 2023 Oct 26 SomaLogic, Inc. (NasdaqGM:SLGC) entered into a definitive agreement to acquire to acquire Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others for approximately $570 million in a reverse merger transaction. Oct 06
SomaLogic, Inc. (NasdaqGM:SLGC) entered into a definitive agreement to acquire to acquire Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others for approximately $570 million in a reverse merger transaction. Oct 05
Second quarter 2023 earnings released: US$0.22 loss per share (vs US$0.82 loss in 2Q 2022) Aug 09
Standard BioTools Inc. to Report Q2, 2023 Results on Aug 08, 2023 Jul 26
High number of new directors Jun 21
Senior VP & CFO recently bought €179k worth of stock May 23
Standard BioTools Inc. Announces NGS Library Preparation as an Upgrade on the X9 High-Throughput Genomics System May 19 Standard BioTools Inc. Appoints Jeffrey Black as Chief Financial Officer
First quarter 2023 earnings released: US$0.21 loss per share (vs US$0.99 loss in 1Q 2022) May 11
Standard BioTools Inc. Announces Retirement of Gerhard Burbach as Member of the Board of Directors May 05
Standard BioTools Inc. Provides Earnings Guidance for the Year 2023 Feb 16
Full year 2022 earnings released: US$2.43 loss per share (vs US$0.78 loss in FY 2021) Feb 16
Standard BioTools Inc. to Report Q4, 2022 Results on Feb 14, 2023 Feb 01
Standard Biotools Inc. Appoints Betsy Jensen as Chief Human Resources Officer Jan 04
Standard BioTools Inc. (NasdaqGS:LAB) announces an Equity Buyback for $20 million worth of its shares. Nov 29
Third quarter 2022 earnings released: US$0.37 loss per share (vs US$0.18 loss in 3Q 2021) Nov 10
Standard BioTools Inc. to Report Q3, 2022 Results on Nov 08, 2022 Oct 26
Standard BioTools Releases the X9 Real-Time PCR System, Its Most Productive and Flexible High-Capacity Genomics Platform Oct 07
Second quarter 2022 earnings released: US$0.82 loss per share (vs US$0.23 loss in 2Q 2021) Aug 10
Standard BioTools Inc. Reports Impairment Charges for the Second Quarter Ended June 30, 2022 Aug 10
Standard BioTools Inc. to Report Q2, 2022 Results on Aug 08, 2022 Jul 26
Standard BioTools Inc. Announces Resignation of Nicholas Khadder as Senior Vice President, General Counsel and Corporate Secretary Jul 09
Standard Biotools Inc. Announces Resignation of Bradley Kreger, Senior Vice President, Global Operations Jun 29
Standard BioTools Inc.(NasdaqGS:LAB) dropped from Russell Microcap Value Index Jun 26
First quarter 2022 earnings released: US$0.99 loss per share (vs US$0.25 loss in 1Q 2021) May 07
Standard BioTools Inc., Annual General Meeting, Jun 15, 2022 May 02
Standard BioTools Inc. to Report Q1, 2022 Results on May 05, 2022 Apr 23
Standard Biotools Inc. Launches Hyperion+ Imaging System, the New Standard in High-Plex Spatial Imaging Apr 12 Fluidigm Corporation Announces Board Changes
Fluidigm Corporation Announces Management Changes Mar 30
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 19
Third quarter 2021 earnings released: US$0.18 loss per share (vs US$0.083 loss in 3Q 2020) Nov 09
Fluidigm Corporation Announces the Publication of New Data Further Validating the Potential of Its Mass Cytometry Technologies Sep 01
Second quarter 2021 earnings released: US$0.23 loss per share (vs US$0.18 loss in 2Q 2020) Aug 08 Fluidigm Corporation Revises Earnings Guidance for the Fiscal Year 2021
Fluidigm Corporation Announces Launch of CyTOF XT May 26
First quarter 2021 earnings released: US$0.25 loss per share (vs US$0.23 loss in 1Q 2020) May 08 Fluidigm Corporation Provides Revenue Guidance for the Second Quarter of 2021
Fluidigm Corporation Announces FDA Grants Emergency Use Authorization for Home Collection Kit for Advanta Dx SARS-CoV-2 RT-PCR Assay Mar 03
Full year 2020 earnings released: US$0.74 loss per share (vs US$0.97 loss in FY 2019) Feb 28
Revenue misses expectations Feb 28
Full year 2020 earnings released: US$0.74 loss per share (vs US$0.97 loss in FY 2019) Feb 13
Revenue misses expectations Feb 13
Fluidigm Corporation Announces Collaboration with Zhejiang Puluoting Health Technology Co. Ltd to Market Fluidigm CyTOF Technology to Clinical Labs in China Feb 11
New 90-day high: €5.95 Feb 11
Fluidigm Corporation Announces Fluidigm® Mass Cytometry Technology and the Maxpar® Direct™ Immune Profiling Assay™ Feb 10
Fluidigm Corporation Announces That Helix Specialty Diagnostics Is Partnering with Genomic LTC DX to Provide Covid-19 Testing Using the Advanta™ Dx SARS-CoV-2 RT-PCR Assay on the Fluidigm® Biomark™ HD System Jan 28
Revenue & Expenses Breakdown
How Standard BioTools makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History DB:FLB Revenue, expenses and earnings (USD Millions) Date Revenue Earnings G+A Expenses R&D Expenses 30 Sep 24 156 -171 140 55 30 Jun 24 136 -165 128 26 31 Mar 24 127 -136 113 35 31 Dec 23 106 -75 88 26 30 Sep 23 105 -76 86 51 30 Jun 23 105 -84 87 34 31 Mar 23 97 -131 93 40 31 Dec 22 98 -190 102 34 30 Sep 22 109 -179 105 2 30 Jun 22 112 -163 107 0 31 Mar 22 124 -117 102 0 31 Dec 21 131 -59 99 0 30 Sep 21 137 -68 108 0 30 Jun 21 148 -60 106 0 31 Mar 21 143 -56 103 0 31 Dec 20 138 -53 98 0 30 Sep 20 126 -48 85 0 30 Jun 20 113 -55 83 0 31 Mar 20 115 -55 84 0 31 Dec 19 117 -65 84 0 30 Sep 19 117 -67 88 8 30 Jun 19 120 -69 87 15 31 Mar 19 118 -71 84 23 31 Dec 18 113 -59 80 0 30 Sep 18 108 -55 74 53 30 Jun 18 104 -56 74 45 31 Mar 18 102 -57 76 38 31 Dec 17 102 -61 80 31 30 Sep 17 99 -68 86 0 30 Jun 17 97 -72 87 0 31 Mar 17 101 -73 90 0 31 Dec 16 104 -76 93 38 30 Sep 16 110 -71 93 0 30 Jun 16 117 -61 91 0 31 Mar 16 117 -57 88 0 31 Dec 15 115 -53 83 0 30 Sep 15 117 -51 78 0 30 Jun 15 118 -56 79 0 31 Mar 15 117 -53 75 0 31 Dec 14 116 -53 71 0 30 Sep 14 104 -47 66 0 30 Jun 14 92 -37 58 0 31 Mar 14 82 -28 52 0 31 Dec 13 71 -17 48 0
Quality Earnings: FLB is currently unprofitable.
Growing Profit Margin: FLB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: FLB is unprofitable, and losses have increased over the past 5 years at a rate of 21.4% per year.
Accelerating Growth: Unable to compare FLB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FLB is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-0.7%).
Return on Equity
High ROE: FLB has a negative Return on Equity (-25.46%), as it is currently unprofitable.
Return on Capital Employed
Discover strong past performing companies Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}